Introduction
Although the role of the immune system in influencing cancer pathogenesis was controversial for most of the 20th century, in recent years Schreiber (2005) and others have made a convincing argument for the existence of cancer immunosurveillance (Dunn et al., 2004) . Their proposed model of 'immunosurveillance and immunoediting' emphasizes the interplay between the immune system and evolving cancers. In this model, early tumor cells that express tumor-specific markers are eliminated, while less immunogenic tumor variants persist. In later disease, tumors escape immune control by numerous mechanisms including the expression of immunosuppressive factors such as TGF-b, PGE2, IL-10, gangliosides and indoleamine 2, 3-dioxygenase. Additionally, the tumor microenvironment is often enriched with immunosuppressive populations of cells, particularly CD4 þ CD25 þ regulatory T cells (T regs ) and plasmacytoid dendritic cells (DCs) (Rabinovich et al., 2007) . These mechanisms may explain the often limited success of strategies aimed at the induction of immune responses against tumor associated antigens. Indeed, clinical trials employing a range of immunotherapeutic strategies have had somewhat limited success in inducing immune sensitization against tumor antigens or clinical responses. Recent progress in the study of innate immunity has redirected investigators in the field of cancer immunotherapy towards the use of microbial derived adjuvants. This experience has yielded some promising results and provided an opportunity to study interactions between conventional therapies such as cytotoxic chemotherapy and radiation and immunotherapies.
TLRs in innate and adaptive immunity
The study of invertebrate immunology has provided many insights into the function of 'innate' components of the mammalian immune system; the discovery of Toll-like receptors (TLRs) being a notable example. Through investigations into the developmental biology of fly larvae, the gene Drosophila Toll was first identified and linked to the transmembrane receptor it encodes (Hashimoto et al., 1988) . Demonstration that lossof-function mutations in the Toll gene result in susceptibility to fungal infection, but not to Gram-negative bacterial infection (Lemaitre et al., 1996) led to the extensive characterization of immune responses in Drosophila. A parallel search for related features of immunity in mammals followed (Medzhitov et al., 1997) . To date, eleven 'TLRs' with homology to invertebrate counterparts have been identified in humans. These receptors recognize highly conserved molecular patterns common to pathogens, termed pathogen-associated molecular patterns . Examples of pathogen-associated molecular patterns and corresponding TLRs include: doublestranded RNA, which is recognized by TLR3 (Alexopoulou et al., 2001) , Lipopolysaccharide (LPS), which is recognized by TLR4 (Poltorak et al., 1998) and DNA containing the unmethylated CpG motif, which is recognized by TLR9 (Hemmi et al., 2000) . Additionally, endogenous ligands of TLRs have been identified, including a number of endogenous molecules (for example, heat-shock proteins) (Wallin et al., 2002) and degradation products of endogenous macromolecules (for example, heparan sulfate) (Johnson et al., 2002) .
An extensive investigation into the molecular basis of TLR function has been undertaken in recent years (Akira and Takeda, 2004) . Though considerable overlap exists between implicated pathways, signaling through the various TLRs may initiate discreet downstream molecular events (Figure 1 ). Most TLRs act through the myeloid differentiation primary response protein 88 (MyD88) and tumor necrosis factor receptor-associated factor 6 to activate nuclear factor kB (NF-kB) and mitogen-activated protein kinases and induce gene transcription. MyD88-independent signaling through the TIR-domain-containing adapter inducing IFN-b (TRIF) and the TRIF-related adapter molecule following TLR 3 and 4 binding, induce the transcription factor interferon regulatory factor-3 (IRF-3). At the cellular level, TLR binding results not only in the activation of effectors of innate immunity, but also in the induction of adaptive responses. Ligation of TLRs expressed by antigen presenting cells may result in the expression of co-stimulatory molecules (for example, CD80 and CD86) and cytokines (for example, IL-6 and IL-12) (Macagno et al., 2007) . Moreover, TLR-primed dendritic cells induce antigen-specific high avidity CD8 (Xu et al., 2003 (Xu et al., , 2006 and type-I polarized CD4 T-cell responses (Wesa et al., 2007) . These findings have provided a foundation for immunotherapeutic strategies targeting tumor-associated antigens for the treatment of malignancies.
TLR ligands in cancer immunotherapy
Potential therapeutic applications of microbial pathogen derived products have long been recognized. Indeed, William B Coley's 'toxin', a preparation of killed serratia and streptococci, which he administered to patients with various malignancies and the addition of adjuvants including microbial products (for example, Freund's adjuvant) to vaccine preparations represent two important examples. In recent years, Janeway and colleagues provided mechanistic insight into the basis of such classical immunization strategies through the identification of TLRs and pathogen-associated molecular patterns . Through the induction of antigen-presenting cell maturation and secretion of proinflammatory chemokines and cytokines, TLRs provide a link between innate and adaptive immunity, which may be exploited to induce robust immune responses against specific antigens. The therapeutic potential of TLR-targeted therapies for a variety of clinical indications is becoming increasingly evident (van Duin et al., 2006) . Established cancer therapeutics, including the cell wall skeleton of Bacillus Calmette-Guerin (BCG-CWS) and Imiquimod, used for the treatment of bladder cancer and basal cell cancer respectively, derive functionality through TLR signaling; the former acts through TLR 2 and TLR 4, while the latter acts on TLR 7 (Tsuji et al., 2000; Ambach et al., 2004) . Moreover, numerous preclinical and clinical trials have utilized TLR agonists as vaccine adjuvants. CpG ODNs, which act on TLR 9, have been studied most extensively in this setting and appear to enhance vaccine immunogenicity Kochling et al., 2003) . Other TLR ligands have therapeutic potential as well. In our ongoing clinical trial of a lipopolysaccharide (TLR 4 agonist) primed, HER-2/neu peptide-pulsed dendritic cell vaccine for patients with HER-2/neu overexpressing ductal carcinoma in situ (DCIS) of the breast (Czerniecki et al., 2007) , consistent T-cell sensitization to HER-2/neu has been noted. Limitations of such strategies are likewise apparent, as consistent clinical responses remain an elusive goal. While improvements in the design of immunotherapies may result in better clinical efficacy, conventional adjunctive therapies may have a role as well. Immunomodulatory effects of cytotoxic chemotherapy may result in enhanced immunogenicity of TLRtargeted immunotherapies. Conversely, TLR-targeted therapy may enhance subsequent responses to chemotherapy. Such combinations have been explored in a number of preclinical studies, sometimes with promising results (Lake and Robinson, 2005; Bourquin et al., 2006; Shi et al., 2007) . For example, Shi et al. (2007) demonstrated enhanced chemo-sensitivity of chronic lymphocytic leukemia cells after tolerizing treatment with the TLR7 agonist, S28690. Moreover, the addition of treatment with PF-3512676 (a TLR9 agonist) was recently shown to yield improved clinical responses to chemotherapy in patients with non-small cell lung cancer (Krieg, 2007) . While radiation therapy has not been explored as extensively, it too is emerging as a potentially powerful tool when combined with immunotherapies.
Revisiting the role of radiation
Immunomodulatory effects of radiation Radiation therapy has traditionally been viewed as immunosuppressive (Cole, 1986; James et al., 1989; Wasserman et al., 1989) . Lymphocyte radiosensitivity is well established and remains the dominant explanation for this effect. However, substantial evidence suggests more varied effects of radiation on the immune system, prompting the re-characterization of radiation as 'immunomodulatory' rather than immunosuppressive (McBride et al., 2004) . Increased expression of proinflammatory cytokines, including TNF-a and IL-1b following radiation has been reported (Hallahan et al., 1989; Ishihara et al., 1995; Nemoto et al., 1995; Hong et al., 1999) . These observations suggest a potential role for radiation in signaling 'danger' and, perhaps, in the activation of antigen presenting cells (McBride et al., 2004) . Notwithstanding this, studies aimed at determining the effects of radiation on antigen-presenting cell phenotype, cytokine expression and function have been somewhat contradictory. While alterations in DC phenotype have been demonstrated infrequently (Cao et al., 2004) , a number of investigators have noted changes in the cytokine secretory profile and function of DCs following irradiation. For example, Shigematsu et al. (2007) , reported enhanced expression of IL-2, IL-12 and IFN-g by irradiated DCs. This expression profile correlated with greater T-cell proliferation following coculture with irradiated compared to non-irradiated DCs. In contrast, Merrick et al. (2005) reported decreased IL-12 production and impaired naive T-cell priming by irradiated compared to non-irradiated DCs. The disparity between these findings may be attributable to the different irradiation strategies and models utilized in these studies. The effect of radiation on DC antigen presentation also remains controversial with a number of studies suggesting significant modulation of, or no effect on, T-cell stimulatory capacity. Interestingly, Liao et al. (2004) reported impaired T-cell priming against endogenously processed antigen and enhanced priming against exogenous peptide pointing to a more complex interplay between radiation and DC function. A number of factors may explain why the consistent characterization of immune responses to radiation remains elusive including differences in radiosensitivity or reactivity of different cell and tissue types, and dose-dependent effects. The latter have been explored in a number of studies, some of which suggest that lower doses of radiation have a greater potential to enhance immune responses (Hashimoto et al., 1999; Cao et al., 2002; Ina and Sakai, 2005; Shigematsu et al., 2007) .
Enhancement of antitumor effector mechanisms
The efficacy of radiation therapy in the treatment of many tumor types is well established. While radiation induced tumor regression is largely the result of directed damage to radiosensitive tumor cells, evidence points to a number of additional immune-mediated mechanisms. Suppressor populations of T cells may be more radiosensitive than their effector counterparts and, conversely, tumor-specific effector T cells may be relatively radio-resistant (North, 1986; Dunn and North, 1991) . This notion, as it relates to contemporary definitions of regulatory T cells (T regs ), has not been extensively explored. However, one recent study implicated T reg depletion in the enhanced efficacy of adoptive T-cell immunotherapy for transplanted melanomas following whole-body irradiation in a murine model (Antony et al., 2005) . Enhanced functionality of adoptively transferred T cells following radiation induced lympho-depletion has also been linked to increased availability of homeostatic cytokines . A number of studies have measured the effects of low-dose total-body irradiation on the relative size of T-cell subpopulations and expression of cytokines associated with T-cell activation. In one report, lowdose irradiation following transplantation of a hepatoma cell line in a rat model resulted in an increased proportion of CD8-positive splenocytes, increased numbers of tumor infiltrating lymphocytes, increased TNF-a and IFN-g expression and decreased TGF-b expression. This response correlated with a reduction in metastases (Hashimoto et al., 1999) . Another study demonstrated an increased CD4:CD8 T cell ratio, and decreased expression of TGF-b and VEGF following low-dose total body-irradiation, which correlated with delayed tumor growth in mice transplanted with the Lewis lung carcinoma cell line (Miller et al., 2003) . The so-called 'abscopal effect', whereby radiation results in reduced tumor growth outside the direct radiation field, suggests radiation-induced immune-mediated mechanisms. The fact that this effect may be enhanced with Fms-like tyrosine kinase receptor 3 ligand (Flt-3L), a stem cell mobilizing factor that augments the number of circulating DC precursors, in immunocompetent mice and abrogated in T-cell-deficient mice lends additional support to this contention (Demaria et al., 2004) .
Stromal effects
Radiation may induce immune-mediated targeting of tumor stroma. Antigen released following tumor irradiation may be presented by stromal cells for subsequent destruction by CTLs. This mechanism was recently demonstrated by Zhang et al. (2007) in experiments utilizing immunodeficient mice given tumor transplants. Only the combination of irradiation and adoptive transfer of CTLs resulted in tumor regression. This regression correlated with increased expression of tumor-specific peptide-MHC complexes as delineated using a tumor antigen/MHC complex-specific TCR tetramer. Direct effects of radiation on the stroma may play a role in enhancing immune-mediated tumor regression as well. Induced modulation of the expression of adhesion molecules, such as accumulation of P-selectin in the lumen of tumor vasculature, may enhance infiltration of immune effectors into the tumor stroma (Hallahan et al., 1998; Hallahan and Virudachalam, 1999) .
Enhancement of tumor antigen recognition
Induction of antitumor immunity by radiation may result from enhanced tumor antigen recognition. Irradiation induces tumor cell apoptosis, or necrosis secondary to vascular injury (Acker et al., 1998) . Subsequent phagocytosis of apoptotic bodies by DCs and initiation of antitumor T-cell responses through cross presentation may ensue if DC maturation signals are concomitantly present. A number of studies have suggested that necrosis, but not apoptosis, is associated with DC maturation signals (Basu et al., 2000; Sauter et al., 2000) However, more recently evidence that some apoptotic pathways do induce DC maturation and antitumor immunity has emerged (Scheffer et al., 2003) . Sublethal irradiation of tumors may also result in enhanced expression of surface molecules recognized or targeted by immune effectors, as is suggested by studies demonstrating increased expression of the MHC class I antigen, H-2D, by melanoma cells (Hauser et al., 1993) and tumor associated antigens including carcinoembryonic antigen by gastric adenocarcinoma cells (Hareyama et al., 1991) . Increased expression of the death receptor Fas following radiation has also been demonstrated in a transgenic carcinoembryonic antigen-expressing tumor model and associated with greater susceptibility to CTLmediated tumor cell lysis (Chakraborty et al., 2003) .
Combining immunotherapy and radiation
Building upon the hypothesis that radiation can enhance anti-tumor immunity, investigators have begun to combine radiation therapy with immunotherapies as was recently reviewed (Demaria et al., 2005a) . Generally, such efforts employ radiation to induce tumor cell apoptosis or necrosis with resultant antigen release for subsequent presentation by DCs. Several investigators have studied combinations of intra-tumoral or peri-tumoral DC administration (Nikitina and Gabrilovich, 2001) , or administration of Flt-3L (Chakravarty et al., 1999 (Chakravarty et al., , 2006 Demaria et al., 2004) combined with irradiation, yielding promising results. Administration of a recombinant viral vaccine-expressing tumor-associated antigen(s) and costimulatory molecules in combination with tumor irradiation may capitalize on the capacity of radiation to enhance immune recognition of antigen-expressing tumor cells. Such an effect was recently demonstrated and linked to radiation induced upregulation of Fas on tumor cells (Chakraborty et al., 2004) . A number of investigators have explored combinations of cytokine therapy and irradiation; studied cytokines include IL-3 (Chiang et al., 2000) , IL-12 (Seetharam et al., 1999; Lohr et al., 2000) and TNFa (Weichselbaum et al., 1994) . Local radiation therapy in combination with CTLA-4 blockade is an additional novel approach for overcoming mechanisms of tumor tolerance. This combination was recently demonstrated to induce anti-tumor CD8 T cells in a poorly immunogenic murine adenocarcinoma model, whereas CTLA-4 blockade alone did not (Demaria et al., 2005b) . Collectively, these studies encourage optimism regarding the potential of combined immunotherapy and radiotherapy.
Radiation-induced TLR signaling
Investigations into the function TLRs have provided mechanistic insight into the actions of several established cancer therapies. Recent evidence suggests that TLR-dependent mechanisms contribute to the therapeutic effects of radiation as well (Figure 2 ). It has been widely hypothesized that tumor irradiation activates effectors of innate immunity through the induction of tumor cell apoptosis and the release of endogenous TLR agonists. The observation that such ubiquitous factors as heat-shock proteins and uric acid can act through TLRs and induce DC maturation (Gallucci et al., 1999) supports this mechanism as does the demonstration that immature DCs, when administered into irradiated tumors, induce antitumor immunity (Kim et al., 2004) . Most recently, the high-mobility-group box 1 alarmin protein, released by dying tumor cells, was shown to act on TLR4 expressed by DCs. Moreover, binding of TLR4 was demonstrated to increase the efficiency of tumor antigen processing and presentation (Apetoh et al., 2007) . TLR dependent mechanisms may play a role in systemic therapies as well. Whole body irradiation was recently shown to increase bacterial translocation and circulating levels of the TLR 4 agonist lipopolysaccharide. This phenomenon was associated with enhanced anti-tumor immunity in an adoptive transfer model . When considered together, such evidence provides a strong rationale for the use of radiation therapy as an immune intervention; a paradigm shift from the traditional view of radiation therapy as a cytotoxic therapy. The capacity of radiation to elicit the expression of TLR ligands systemically after gastrointestinal tract irradiation, or locally after tumor irradiation, may prove valuable in conjunction with other immunotherapies.
Potentiating anti-tumor immunity with radiation therapy and TLR agonists
Few investigators have directly studied the combination of radiation and TLR-targeted therapies; this despite recognition that the therapeutic effects of radiation may be dependent upon TLR signaling. Mason et al. (2005) recently demonstrated a markedly enhanced tumor response to radiation therapy following peri-and intratumoral injections of the TLR agonist, CpG, in a murine fibrosarcoma model (Milas et al., 2004) . In light of the recently elucidated role of TLRs in radiation induced responses, this effect may reflect synergy at the level of TLR signaling. Further investigations are required to determine the applicability of such approaches but potential implications of these findings are broad. TLRtargeted therapy may sensitize a wide range of tumor types to radiation therapy and result in a reduction of the radiation dose necessary to achieve a therapeutic effect. Such approaches may become increasingly important as new TLR-targeted therapies emerge.
Future directions/conclusions
A role for novel neoadjuvant immunotherapies is emerging and will result in opportunities to study their interplay with conventional treatments, such as chemotherapy and radiation. Radiation therapy may be an important adjunct to immunotherapies with the potential to enhance the antigenicity of tumors and promote stromal targeting. Perhaps more importantly, radiation therapy may activate effectors of innate immunity through TLR-dependent mechanisms. The relative contributions of these distinct radiation-induced mechanisms to anti-tumor immunity remain unclear. Moreover, specific mechanisms may be more important in some specific clinical settings than in others (for example, radiation-induced bacterial translocation following irradiation of the gastrointestinal tract). Additionally, TLR-targeted therapies may have widespread utility as sensitizing agents for subsequent radiotherapy or chemotherapy. Locally or systemically administered TLR agonists, local radiation therapy and whole-body irradiation are emerging as complimentary tools that may be combined to elicit an anti-tumor immune response. As we learn more about the immune-mediated mechanisms initiated by conventional cancer therapies we will be better able to utilize these modalities and emerging immunotherapies in combination. 
